Toboroz
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703· 3. fázis· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Forrás
Contact: Zhihu Li, Master
Toboroz
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
NCT07407803· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Jing Li, Bachelor
Toboroz
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07218341· 4. fázis· Eli Lilly and Company· Forrás
Contact: Jie Cui (principal investigator)
Még nem toboroz
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
NCT07483684· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Forrás
Contact: Zhihu Li, Master
Toboroz
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
NCT07284134· 3. fázis· Shanghai Junshi Bioscience Co., Ltd.· Forrás
Contact: Zhihu Li, Doctor
Toboroz
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049· 3. fázis· Evopoint Biosciences Inc.· Forrás
Contact: Yingjie zhao
Toboroz
Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
NCT07052669· 3. fázis· Sun Yat-sen University· Forrás
Contact: Shihong Wei, M.Med
Toboroz
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT07003074· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Forrás
Contact: Yanxiang Guo, Bachelor
Toboroz
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263· 3. fázis· Akeso· Forrás
Contact: Shihong Wei, M.D.
Toboroz
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
NCT06829771· 1/2. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Junfeng Jiang, Master
Toboroz
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
NCT06860971· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Jun Wang, Bachelor
Toboroz
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
NCT06854445· 2. fázis· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Forrás
Contact: Junfeng Jiang, Master
Toboroz
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
NCT06760039· 1/2. fázis· Sun Yat-sen University· Forrás
Contact: Junfeng Jiang
Toboroz
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006· 3. fázis· Shanghai Henlius Biotech· Forrás
Contact: Ying Li
Fut, nem toboroz
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921· 3. fázis· Jiangsu Simcere Pharmaceutical Co., Ltd.· Forrás
Fut, nem toboroz
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900· 3. fázis· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Forrás
Fut, nem toboroz
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
NCT06561607· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Még nem toboroz
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
NCT06475599· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Qingming Zhang, Bachelor
Fut, nem toboroz
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
NCT06238843· 3. fázis· Innovent Biologics (Suzhou) Co. Ltd.· Forrás
Fut, nem toboroz
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312· 3. fázis· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Forrás
Toboroz
Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical Cancer
NCT06241781· 2. fázis· Grit Biotechnology· Forrás
Contact: Qingming Zhang
Toboroz
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
NCT06300177· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Xiting Liu, Bachelor
Toboroz
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983· 3. fázis· Jiangsu Alphamab Biopharmaceuticals Co., Ltd· Forrás
Contact: Yingxia Tian
Még nem toboroz
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
NCT05990127· 3. fázis· Akeso· Forrás
Contact: Zhifang Yao, M.D.
Fut, nem toboroz
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608· 3. fázis· Summit Therapeutics· Forrás
Toboroz
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
NCT05862337· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Yan Yang, Bachelor
Még nem toboroz
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT05767892· 3. fázis· Suzhou Puhe Pharmaceutical Technology Co., LTD· Forrás
Contact: Lei Yang
Fut, nem toboroz
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
NCT05716087· 2. fázis· Guangzhou Lupeng Pharmaceutical Company LTD.· Forrás
Fut, nem toboroz
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
NCT05365178· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Fut, nem toboroz
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
NCT05180734· 3. fázis· Shanghai Junshi Bioscience Co., Ltd.· Forrás
Fut, nem toboroz
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
NCT04854668· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás